Exploring tumor dynamics and responses of prostate cancer to IL-27 based treatment combinations through biodynamic imaging and RNA sequencing analyses

We use Biodynamic imaging and transcriptomics to study the response of cells to various drugs applied ex-vivo to measure and correlate the intracellular motion as a biomarker of tumor samples therapies. Prostate Cancer has been used as a model in this study. The control and IL-27 treated tumors were exposed to chemo/immunotherapy drugs ex vivo and BDI was used to profile changes in the TME. The integration of these techniques will enable informed decision-making regarding combination treatment strategies for PCa. Overall design: This study used a subcutaneous PCa in vivo model. The control and IL-27 treated tumors were exposed to chemo/immunotherapy drugs ex vivo and BDI was used to profile changes in the TME. Additionally, RNA-sequencing was used to elucidate the molecular changes occurring in the cells in response to various treatment combinations. The mouse adenocarcinoma cell line TRAMP-C2-Ras was used to create a vector for delivering various drugs to the Male C57/BL6 mice (8-10 weeks of age). Stranded RNASeq libraries were created and paired-end sequencing was performed to study the effects of the drugs in a tumor microenvironment. Biodynamic analysis produces Doppler spectra as functions of time for each tested well. The average spectra of all cold (empty vector treated tumors) and hot (IL-27 treated) tumors are identified, and we see the migration of infiltrated immune cells, notably T-Cells that were promoted by the IL-27 treatment of the mouse in vivo. We use RNASeq to look for enhanced T-Cell components in Hot tumors relative to the Cold tumors.